Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells (Q36673777)
scientific article published on January 2004
Language:
(P31) (Q13442814)
(P50) (Q60655880)
(P304) 236-244
(P407) (Q1860)
(P433) 1
(P478) 90
(P577) Thursday, January 1, 2004
(P1433) (Q326309)
(P1476) "Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells" (language: en)
(P2093) S Okubo
J Kurebayashi
T Otsuki
Y Yamamoto
H Sonoo
(P2860) (Q34992235)
(Q34528550)
(Q40703800)
(Q40718807)
(Q34665985)
(Q40732059)
(Q34522758)
(Q34125874)
(Q36623819)
(Q34578321)
(Q38282688)
(Q34428773)
(Q27860884)
(Q34112985)
(Q40857196)
(Q36620845)
(Q36617556)
(Q36618907)
(Q36135429)
(Q36081088)
(Q36080814)
(Q33203153)
(Q44175768)
(Q42807740)
(Q41620522)
(Q44323774)
(Q44135091)
(Q44086963)
(Q44049183)
(Q43938023)
(Q43894344)
(Q43843455)
(Q43829350)
(Q43814394)
(Q43755902)
(Q43646623)
(Q43606283)
(Q54031538)
(Q57424632)
(Q73483264)
(Q69900051)
(Q69050922)
(Q73260818)
(Q59566187)
other details
description scientific article published on January 2004

External Links